Advanced searches left 3/3

Methotrexate Psoriasis - Europe PMC

Summarized by Plex Scholar
Last Updated: 02 May 2022

* If you want to update the article please login/register

Internet-based survey intervention improves adherence to methotrexate among psoriasis patients.

Background While it is known that psoriasis patients have poor adherence to both topical and systemic drugs, adherence to methotrexate is not well defined, and ways to improve methotrexate adherence have yet to be investigated. 80% of control patients received methotrexate correctly during the week of a follow-up visit, with 100% of digital intervention patients and 80% of control patients taking methotrexate correctly. In comparison to the nonintervention group, the digital intervention did not appear to raise disease severity in the intervention group much.

Source link: https://europepmc.org/article/MED/35485939


Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis.

Background pharmacoeconomic studies comparing the cost of adalimumab biosimilars versus the originator and conventional medications in psoriasis are missing. Design and methods of research To determine the cost per responder of adalimumab biosimilars to the originator and methotrexate for psoriasis therapy, compare the originator and methotrexate. respectively, the results were calculated considering the PASI75 response rate at 16 weeks, the cost per responder for MSB11022 and ABP 501 was € 500 versus 1,849 versus 1,949, respectively.

Source link: https://europepmc.org/article/MED/35466843


Sex-differential downregulation of methotrexate on plasma viscosity and whole blood viscosity in psoriasis.

Methotrexate therapy has been used in a psoriatic patients, from October 22, 2018, to December 28, 2019, and 111 age-matched healthy controls. However, only hCRP was positively related to the psoriasis area severity index score, although the psoriasis area severity index score was only elevated. The effect of MTX on WBV, PV, hCRP, and BP was determined by sex, according to a sex-specific downregulation, indicating that the effect of MTX on cardiovascular disease was linked to sex.

Source link: https://europepmc.org/article/MED/35466929


MTHFR Gene Polymorphism Association With Psoriatic Arthritis Risk and the Efficacy and Hepatotoxicity of Methotrexate in Psoriasis.

Aims To determine whether MTHFR rs1801131 and rs1801133 SNPs are related to concomitant psoriatic arthritis, as well as investigate the equitability and hepatotoxicity of MTX in Han Chinese patients with psoriasis. PsA patients with PsA were more prevalent in PsA patients than those with PsO and healthy controls, according to the study. Patients with the rs1801133 TT genotype had a 90 percent higher risk of baseline PASI response rates to MTX were significantly higher in patients with the rs1801133 TT genotype than those with the CT and CC genotypes. The rs1801133 CT+TT genotype was more prevalent in PsA patients with abnormal liver function in comparison to those with normal liver function. Conclusions MTHFR polymorphism association with PsA risk and the Chinese population's low-dose MTX's efficacy and hepatotoxicity were among the study's findings.

Source link: https://europepmc.org/article/MED/35479943


Shikonin combined with methotrexate regulate macrophage polarization to treat psoriasis.

This study was intended to see if shikonin and methotrexate might have slowed psoriasis progression by regulating macrophage polarization by in vivo and in vitro experiments. In each group, mouse lesions were scored, so the final score was calculated as psoriasis area and severity index score, and not as psoriasis area and severity index score. The skin lesion tissue from mice was isolated and used for hematoxylin staining and immunohistochemistry assay. In imiquimod-induced psoriasis mice, shikonin and methotrexate combined with methotrexate had protective effects by lowering erythema and PASI scores, lowering backer score and epidermal thickness, and specifically regulating macrophage polarization. In LPS-stimulated RAW264. 7 cells, shikonin and methotrexate regulated M1/M2 polarization and altered the concentrations of M1 markers. Psoriasis progression can be reduced by limiting macrophage polarization, which may be useful in the treatment of psoriasis.

Source link: https://europepmc.org/article/MED/35485255


Evaluation of methotrexate-loaded surfactants, ceramides and cholesterol-based lamellar phases as a topical treatment for psoriasis.

Objective Psoriasis is a persistent inflammatory skin disease. Oral or subcutaneous methotrexate is a first-line antipsoriatic drug that has no side effects, even at low doses. This work reviewed two MTX-loaded LPs based on stearic acid, cholesterol, and ceramides, as well as topical treatments for mice with imiquimod-induced psoriasis in mice. Positive health monitoring was used with Dexamethasone cream. Key findings C1CH and C1CHCE demonstrated potent immunomodulatory activity, as well as extensive microstructural skin remodelling on the epidermis and dermis.

Source link: https://europepmc.org/article/MED/35355075


International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis.

Importance A precise dosing regimen for methotrexate in psoriasis is missing, and this may result in a suboptimal treatment. Because methotrexate is inexpensive and widely available, a single dosing regimen could potentially improve patients with psoriasis worldwide. Objectives: To reach international consensus among psoriasis experts on a single dosing regimen for treatment of psoriasis in adult and pediatric patients with methotrexate in adult and pediatric patients with psoriasis, as well as potential future research areas. In three rounds, participants were divided into three groups: Between September 2020 and March 2021, a research study involving a modified eDelphi procedure that was invented and released by the Amsterdam University Medical Center and concluded by 180 participants worldwide between September 2020 and March 2021. Conclusions and relevance In this eDelphi consensus research, consensus was reached on 20 of 21 plans involving methotrexate dosing in patients with psoriasis in patients with psoriasis. This agreement may be used to harmonize methotrexate therapy in patients of psoriasis.

Source link: https://europepmc.org/article/MED/35353175


Adalimumab with methotrexate versus adalimumab monotherapy in psoriasis: First-year results of a single-blind randomized controlled trial.

Introduction Adalimumab is mainly prescribed with methotrexate in rheumatoid arthritis due to the enhanced therapy effect and reduced antidrug antibody production in comparison to adalimumab monotherapy. Methods We conducted a controlled trial to determine the safety, pharmacokinetics, and immunogenicity of adalimumab mixed with MTX in chronic plaque psoriasis. In the ADL group, only ADL patients had ADA symptoms. Conclusion : In less patients showing ADA, adalimumab and MTX results resulted in fewer patients showing ADA, with a trend toward a faster PASI75 response, drug retention, and increased serum trough concentrations compared to adalimumab monotherapy.

Source link: https://europepmc.org/article/MED/35276223


Systemic Methotrexate Treatment in 42 Children with Severe Plaque Psoriasis: A Retrospective Study in China.

Background The scientific evidence supporting methotrexate in children with severe plaque psoriasis is sparsif. Objectives Objectives: In a single center in China, objective Objectives To retrospectively assess the efficacy and safety of oral MTX in children with severe plaque psoriasis. We enrolled 42 kids with severe plaque psoriasis who were administrated MTX. Oral MTX's initial weight-based dose ranged from 0. 1 to 0. 3 mg/kg/week. Patients in week 80. 6 and 48. 2% achieved PASI75 and PASI90, respectively, by week 8. At week 12, 72. 2% of patients reached PGA 0/1. PGA and PGA scores significantly dropped from baseline from week 4, along with a CDLQI score increase from week 8. In 9 of the 30 patients, relapse was recorded in 9 of 30 patients, and the average posttherapy disease-free interval was 7. 2 months. Conclusions: The MTX is an affordable and safe option for children with severe plaque psoriasis and needful monitoring.

Source link: https://europepmc.org/article/MED/35176737


Genetic Markers of Therapeutic Efficacy of Methotrexate in Patients with Psoriasis.

We investigated the effects of the MTHFR gene polymorphisms of the MTHFR gene and 2R/3R polymorphisms of the TYMS gene in patients with psoriasis.

Source link: https://europepmc.org/article/MED/35175470

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

Source Recommendations

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions